Serum Institute investing USD 100 million on potential COVID-19 vaccine - (The Economic Times via NewsPoints Desk)

  • The Serum Institute of India (SII) is investing $100 million on a potential COVID-19 vaccine being developed at Oxford University, reported The Economic Times.

  • The company has partnered with AstraZeneca to ensure equitable supply of the AZD1222 vaccine doses to India, as well as low- and middle-income countries.

  • "Our manufacturing facility is ready and we plan to start production in two months," remarked SII chief executive Adar Poonawalla.

  • Regarding how much doses India is likely to get in the first phase, and by when they would be available, Poonawalla said it is too early to give specifics.

  • "However, if the vaccine trials succeed, India will gain access to the doses as it will also be the requirement of the Government of India. And we are certain that everybody will respect if the substantial volumes go to India," he added.

To read more NewsPoints articles, click here.